Novavax, Inc.

As of June 30, 2026, Novavax, Inc. carries a market capitalization of 27.19B, placing it among publicly traded companies globally. Its enterprise value stands at 19.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novavax, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Novavax, Inc. has 164.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.72, and the price-to-book ratio stands at -8.16.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.82B versus a market cap of 27.19B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novavax, Inc. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -155.90, indicating conservative leverage, while an interest coverage ratio of -9.88 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.62, reflecting losses generated across the asset base. The company generates approximately 9.04M in revenue per employee across its workforce of 799.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.75 indicates how many times Novavax, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novavax, Inc. recorded 42.19M in income tax expense. The company reported a pretax loss of -4.29B and -4.33B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Novavax, Inc.'s stock has gained approximately 17.50% over the past 52 weeks. The 50-day moving average sits at 178.21, while the 200-day moving average is 158.16.

Over the twelve months ended June 30, 2026, Novavax, Inc. generated 7.23B in revenue and converted that into -4.33B in net income, yielding earnings per share of -26.42. EBITDA reached -3.78B, while operating income came in at -2.38B.

As of June 30, 2026, Novavax, Inc. holds 12.57B in cash and equivalents against 5.19B in total debt, resulting in a net debt position of 1.75B. Total book value stands at -3.33B, with working capital of 7.70B providing operational flexibility.

Novavax, Inc. produced -644.72M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novavax, Inc. posted a gross margin of 78.60, reflecting its pricing power and cost economics. The operating margin of -32.93 and net profit margin of -59.87 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.80, meaning Novavax, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Novavax, Inc.'s most recent stock split took place on May 10, 2019 with a 20:1 split ratio.

As of June 30, 2026, Novavax, Inc. has an Altman Z-Score of -6.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.